BioVie Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BIVI research report →
Price Chart
About the company
BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis.
- CEO
- Cuong Viet Do
- IPO
- 2020
- Employees
- 13
- HQ
- Carson City, NV, US
Get TickerSpark's AI analysis on BIVI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $10.86M
- P/E
- -0.45
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 1.06
- EV/EBITDA
- -0.10
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -126.02%
- ROIC
- -214.80%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-22,651,733
- Net Income
- $-22,072,863-25.8%
- EPS
- $-3.05+74.8%
- OCF Growth
- -99897.9%
- FCF Growth
- -99897.9%
- 52W High
- $3.79
- 52W Low
- $0.82
- 50D MA
- $1.68
- 200D MA
- $1.52
- Beta
- 0.73
- RSI (14)
- 36
- Avg Volume
- 4.67M
No earnings-call transcripts are available for BIVI yet.
- Free Float
- 99.4%
- Shares Outstanding
- 8.68M
- Float Shares
- 7.50M
of shares held by institutions
32 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Morgan Stanley | 605.47K | ▲ 530.25K |
| Diametric Capital, LP | 256.64K | ▼ 113.36K |
| Vanguard Group Inc | 213.53K | ▲ 84.60K |
| Renaissance Technologies LLC | 127.92K | ▲ 60.00K |
| Citadel Advisors LLC | 95.95K | ▲ 50.66K |
| Vanguard Capital Management LLC | 70.91K | ▼ 13.16K |
| Geode Capital Management, LLC | 70.75K | ▼ 13.45K |
| Philadelphia Trust Co | 50.01K | ▼ 25.00K |
| Vanguard Fiduciary Trust Co | 37.56K | 0 |
| Jane Street Group, LLC | 35.86K | ▲ 13.07K |
| Prelude Capital Management, LLC | 32.58K | ▼ 59.48K |
| Northern Trust Corp | 21.82K | ▲ 7.63K |
Held by 7 ETFs
Biggest fund positions in BIVI by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 28, 26 | Palumbo Joseph M | buy | 4,843 |
| Aug 28, 26 | Chappell Amy Suzon | buy | 727 |
| Aug 28, 26 | KIM JOANNE WENDY | buy | 2,500 |
| Aug 27, 26 | DO CUONG V | buy | 15,210 |
| Jan 5, 26 | Palumbo Joseph M | other | 132,000 |
| Jan 5, 26 | KIM JOANNE WENDY | other | 110,100 |
| Jan 5, 26 | ROGICH SIGMUND | other | 141,100 |
| Jan 5, 26 | ROGICH SIGMUND | other | 70,000 |
| Jan 5, 26 | DO CUONG V | other | 665,300 |
| Jan 5, 26 | Sherman Michael Edward | other | 341,100 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BIVI coverage
Recent articles, reports, and earnings notes.
No research on BIVI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BIVI report →BioVie Highlights Bezisterim Phase II Data, Eyes FDA Path for Phase III Trials
defenseworld.net · Sep 28
BioVie Inc. (BIVI) Discussion of Phase 2 data on bezisterim in Long COVID and Parkinson's with focus on inflammation targets Transcript
seekingalpha.com · Sep 23
BioVie Inc. (BIVI) Discusses Topline Phase 2 ADDRESS-LC Trial Data and the Potential of Bezisterim in Long Covid Transcript
seekingalpha.com · Sep 15
What's Going On With BioVie Stock on Tuesday?
benzinga.com · Sep 15
BioVie Announces Topline Results from Phase 2 ADDRESS‑LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
globenewswire.com · Sep 15
BioVie to Host Conference Call to Discuss Topline Data from Phase 2 ADDRESS-LC Trial and the Potential of Bezisterim in Long Covid
globenewswire.com · Sep 14
Dow closes sharply lower as oil surge fuels inflation fears
proactiveinvestors.com · Sep 8
BioVie advances Parkinson's Phase 3 development program with FDA engagement
proactiveinvestors.com · Sep 8
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.